CVKD
NASD Cadrenal Therapeutics, Inc.$0.9402 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.9402, $0.0648 below the day’s high of $1.0050
- YTD change
- -86.13%
- vs 20-day SMA
- -17.09%
- vs 200-day SMA
- -79.82%
Price ranges
Price & Performance
-3.76 (-80.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.1% away from all-time highs of $101.2500
- CVKD is down 86% since the beginning of the year
- CVKD is down 93% over the past 12 months
- CVKD is down 29% over the past 1 month
- 4% of all CVKD investors are betting against CVKD
CVKD reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -93.4%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0052
- Last 5 days
- -21.65%
- vs 8-day SMA
- -16.89%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
